Literature DB >> 9371376

In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates.

R C Owens1, M A Banevicius, D P Nicolau, C H Nightingale, R Quintiliani.   

Abstract

The microdilution checkerboard technique was utilized to distinguish synergistic activity between tobramycin and four beta-lactams: piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime, and ceftriaxone. Beta-lactam-aminoglycoside combinations were tested against 75 clinical isolates of Pseudomonas aeruginosa, Acinetobacter baumanii, Citrobacterfreundii, Serratia marcescens, and Enterobacter cloacae. Despite in vitro susceptibilities, all isolates demonstrated either synergism or indifference; no antagonism was observed. Against pathogenic gram-negative nosocomial isolates, a greater percentage of synergy was consistently observed with combination regimens containing tobramycin and piperacillin-tazobactam or ticarcillin-clavulanate than with the cephalosporin-containing regimens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371376      PMCID: PMC164171     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.

Authors:  M Hilf; V L Yu; J Sharp; J J Zuravleff; J A Korvick; R R Muder
Journal:  Am J Med       Date:  1989-11       Impact factor: 4.965

2.  Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin.

Authors:  G Archer; F R Fekety
Journal:  J Infect Dis       Date:  1977-09       Impact factor: 5.226

3.  Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients.

Authors:  G P Bodey; R Feld; M A Burgess
Journal:  Am J Med Sci       Date:  1976 Mar-Apr       Impact factor: 2.378

4.  Antimicrobial synergism--an elusive concept.

Authors:  R C Moellering
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

5.  Penicillin-aminoglycoside synergy in experimental Streptococcus viridans endocarditis.

Authors:  M A Sande; R G Irvin
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin.

Authors:  J Klastersky; A Henri; C Hensgens; D Daneau
Journal:  JAMA       Date:  1974-01-07       Impact factor: 56.272

7.  Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes.

Authors:  W M Scheld; D D Fletcher; F N Fink; M A Sande
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

8.  Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin.

Authors:  W R Wilson; R L Thompson; C J Wilkowske; J A Washington; E R Giuliani; J E Geraci
Journal:  JAMA       Date:  1981 Jan 23-30       Impact factor: 56.272

Review 9.  Bacterial resistance to beta-lactams, and its prevention with combination antimicrobial therapy.

Authors:  S L Barriere
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

10.  Pseudomonas bacteremia. Retrospective analysis of 410 episodes.

Authors:  G P Bodey; L Jadeja; L Elting
Journal:  Arch Intern Med       Date:  1985-09
View more
  7 in total

1.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Authors:  Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy.

Authors:  Christina A Sutherland; David P Nicolau
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

Review 5.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 6.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.

Authors:  Devrim Dundar; Metin Otkun
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.